Veklury — Class I drug recall D-0299-2022
Terminated recall by Gilead Sciences, Inc., reported 2022-01-05, distributed nationwide. Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass partic
| Recall number | D-0299-2022 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Gilead Sciences, Inc., Foster City, CA, United States |
| Recall initiated | 2021-12-03 |
| Classified | 2021-12-28 |
| Reported by FDA | 2022-01-05 |
| Terminated | 2022-07-25 |
| Distributed | Nationwide (US) |
| Quantity | 53,473 vials |
| Reason classes | foreign material, specification failure |
| NDC | 61958-2901, 61958-2901-02, 61958-2902, 61958-2902-02 |
| Lot numbers | 2141001-1A, 2141002-1A |
| Expiration dates | 2024-01 |
Product
Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2
Reason for recall
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0299-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.